In an important ongoing study with the ECF regimen as the reference regimen, 5-FU is replaced by capecitabine and cisplatin by oxaliplatin.
在一项正在进行采用ECF作为对照方案的重要研究中，研究者用卡培他滨取代5-FU或用奥沙利铂取代顺铂。Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine .
厄罗替尼布联合卡培他滨同样用于一线药物吉西他滨治疗失败的患者。ObjectiveTo evaluate the efficacy and safety of bevacizumab plus capecitabine in treating metastatic colorectal cancer(mCRC).
目的观察贝伐单抗联合卡培他滨治疗转移性结直肠癌的疗效及不良反应。In addition, capecitabine has been combined with other drugs and is undergoing an investigation in a large phase III trial.
另外，卡培他滨也可与其他药物联合应用，其联合化疗方案正在一项大型III期临床中进行评估。Capecitabine is already approved for use in colorectal cancer and metastatic breast cancer.
卡培他滨已被批准用于结肠直肠癌和乳腺转移癌。Toxic effects of capecitabine and fluorouracil were similar.
卡培他滨和氟尿嘧啶的毒副作用相似。Capacitabine demonstrated a response rate of 34% in a phase II trial from Korea.
在一个韩国的II期临床中卡培他滨单药治疗晚期胃癌的缓解率为34%。This damage leads to side effects such as nausea and hair loss. Patients using capecitabine report fewer side effects.
这种伤害可引起恶心和脱发之类的副作用。而使用卡培他滨的患者报告副作用甚少。Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer
奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察